The mechanisms underlying cellular drug resistance have been extensively studied, but little is known about its regulation. We have previously reported that activating transcription factor 4 (ATF4) is upregulated in cisplatinresistant cells and plays a role in cisplatin resistance. Here, we find out a novel relationship between the circadian transcription factor Clock and drug resistance. Clock drives the periodical expression of many genes that regulate hormone release, cell division, sleep-awake cycle and tumor growth. We demonstrate that ATF4 is a direct target of Clock, and that Clock is overexpressed in cisplatin-resistant cells. Furthermore, Clock expression significantly correlates with cisplatin sensitivity, and that the downregulation of either Clock or ATF4 confers sensitivity of A549 cells to cisplatin and etoposide. Notably, ATF4-overexpressing cells show multidrug resistance and marked elevation of intracellular glutathione. The microarray study reveals that genes for glutathione metabolism are generally downregulated by the knockdown of ATF4 expression. These results suggest that the Clock and ATF4 transcription system might play an important role in multidrug resistance through glutathione-dependent redox system, and also indicate that physiological potentials of Clock-controlled redox system might be important to better understand the oxidative stress-associated disorders including cancer and systemic chronotherapy.
Introduction
Cisplatin is a potent anticancer agent that is used in the treatment of various solid tumors, but the development of resistance is a major obstacle in a clinical setting (Wang and Lippard, 2005) . Several mechanisms are involved in the acquisition of cisplatin resistance, including decreased drug accumulations (Komatsu et al., 2000; Nakayama et al., 2002) , increased levels of cellular glutathione (Lai et al., 1989; Tew, 1994) , and increased DNA-repair activity (Chaney and Sancar, 1996; Husain et al., 1998) . We have been interested in the transcription factors activated in response to cisplatin, which might play a crucial role in cisplatin resistance (Kohno et al., 2005; Torigoe et al., 2005) . We believe that the transcription factors of genes involved in cisplatin resistance are often overexpressed or activated in cisplatin-resistant cells.
Activating transcription factor 4 (ATF4) is a member of the cyclic adenosine monophosphate responsive element-binding (CREB) protein family, and is involved in multiple intracellular stress pathways (Rutkowski and Kaufman, 2003) . ATF4 is ubiquitously expressed in human cancer cells, and is essential for normal cellular proliferation (Fawcett et al., 1999 ), especially the highlevel proliferation required during fetal liver hematopoiesis (Masuoka and Townes, 2002) . ATF4-null cells also show impaired glutathione biosynthesis (Harding et al., 2003) . We have shown previously that ATF4 is upregulated in cisplatin-resistant cell lines and is involved in cisplatin resistance (Tanabe et al., 2003) .
We herein investigate the molecular regulation of ATF4 gene expression and drug resistance. Interestingly, a database search revealed an E-box in the core promoter region of ATF4, and we show that the essential circadian regulator Clock binds to this E-box and is overexpressed in cisplatin-resistant cells. It has been reported previously that Clock/BMAL1 heterodimers activate transcription from E-box elements (Gekakis et al., 1998) ; therefore, ATF4 is thought to be regulated by circadian transcription factors. Downregulation of either Clock or ATF4 using small interfering RNAs (siRNAs) was shown to confer cell sensitivity to anticancer agents. Furthermore, ATF4-overexpressing cells showed multidrug resistance and marked elevation of intracellular glutathione. Knockdown of ATF4 expression lead to downregulation of glutathione metabolism. Our findings indicate an important contribution of both Clock and ATF4 to chemosensitivity.
Results

Overexpression of Clock in cisplatin-resistant cells
We have shown previously that the transcription factor ATF4 is overexpressed in cisplatin-resistant cell lines (Tanabe et al., 2003) . As an E-box is located in the core promoter region of ATF4, we examined the expression levels of the E-box-binding proteins c-Myc, upstream stimulatory factor 1 (USF1), and Clock. Western blotting analysis revealed that the Clock protein was overexpressed in cisplatin-resistant cell lines (Figure 1a) . No significant alteration of c-Myc and USF1 expression was observed between parental and cisplatin-resistant cells. As the Clock/BMAL1 complex regulates the expression of circadian genes (Gekakis et al., 1998) , we analysed the BMAL1 expression. However, the BMAL1 expression was not upregulated in cisplatin-resistant cells (data not shown). Northern blotting analysis revealed that Clock messenger RNA (mRNA) was also overexpressed in cisplatin-resistant cells (Figure 1b) , suggesting that Clock might be involved in the transcriptional regulation of ATF4 by binding to its promoter E-box.
ATF4 is a direct target of Clock
To test whether the ATF4 promoter is a direct target of Clock, we carried out chromatin immunoprecipitation (ChIP) assays using specific primer pairs for the ATF4 promoter region and an anti-Clock antibody. As shown in Figure 1c , this analysis revealed that Clock bound specifically to the E-box region of the ATF4 promoter. A luciferase reporter gene assay showed that both Clock and BMAL1 co-transfection transactivated the ATF4 promoter, and that this transactivation was dependent on an intact E-box, as reporter gene expression was reduced following transfection of a mutated E-box ( Figure 1d ). We also verified the relationship between ATF4 expression and Clock using siRNAs. Inactivation of Clock by siRNA was shown to suppress the promoter activity of ATF4 gene (Figure 1e ) as well as cellular expression level of ATF4 in PC3 cells (Figure 1f ).
Cellular expression of Clock correlates with cisplatin sensitivity
To explore whether Clock overexpression is involved in cisplatin resistance, we examined the correlation between Clock expression and cisplatin sensitivity in 11 lung cancer cell lines (Figure 2a ). Clock expression significantly correlated with cisplatin sensitivity ( Figure 2b ) and with ATF4 expression (Figure 2c ) in these cell lines, but c-myc expression did not (data not shown). To confirm these findings by an alternative approach, we used the siRNA strategy. Downregulation of the cellular expression of the Clock protein conferred cisplatin and etoposide, but not 5-fluorouracil (5-FU), sensitivity to A549 cells (Figure 2d ). Similar results were also obtained when ATF4 expression was downregulated. Clock expression did not correlate with the cellular sensitivity of etoposide, doxorubicin and vincristine at all (data not shown). We next investigated whether downregulation of ATF4 expression overcomes cisplatin resistance in cisplatin-resistant cell line P/ CDP6. As shown in Figure 2e , downregulation of ATF4 expression partially overcomes cisplatin resistance, because the IC 50 value of cisplatin in PC3 cells is about 0.7 mM (data not shown).
Multidrug resistance in ATF4-overexpressing cell lines
In addition to our two previously established ATF4-overexpressing cell lines (Tanabe et al., 2003) , we derived two new cell lines that overexpressed ATF4 (A549/ATF4-5 and A549/ATF4-6) at levels 10-20-fold higher than vector-alone transfectants (A549/pcDNA-1 and A549/pcDNA-2) (Figure 4 ). The ATF4-overexpressing cell lines showed increased resistance to cisplatin, doxorubicin, etoposide, SN-38, and vincristine, but not to 5-FU (Table 1) . To our knowledge, this is the first transcription factor that can induce multidrug-resistant phenotypes.
Intracellular glutathione level and drug resistance-related gene expression in ATF4-overexpressing cells It has been reported that ATF4
-/-cells demonstrate impaired glutathione biosynthesis (Harding et al., 2003) , whereas an increased level of glutathione has been shown to be involved in drug resistance (Lai et al., 1989; Tew, 1994) . Therefore, intracellular glutathione levels were evaluated in ATF4-overexpressing cell lines, and were found to be approximately 12.7-fold higher than in control cells (Figure 3a ). This increase was abolished when cells were treated with the g-glutamylcysteine synthetase inhibitor: buthionine-sulfoximine (BSO) (10 mM). To examine whether Clock and ATF4 are involved in glutathione biosynthesis, A549 cells were transfected with Clock-directed, ATF4-directed, or control siRNA oligomers. Downregulation of both Clock and ATF4 was found to reproducibly suppress intracellular glutathione levels to 75-80% of the control levels ( Figure 3b) .
It has been shown that resistant cells against cisplatin often upregulate both glutamate-cysteine ligase catalytic subunit (GCLC) and glutathione S-transferase p (GSTp) (Saburi et al., 1989; Yao et al., 1995) . On the other hand, the resistant cells against topoisomerasetargeted drugs often downregulate DNA topoisomerase (Takano et al., 1992) . We, therefore, examined drug resistance-related gene expressions in ATF4-overexpressing cells (Figure 4) . Although ATF4-overexpressing cells were resistant to etoposide and SN-38, the expressions of DNA topoisomerase I and IIa were not downregulated. As we expected, the expressions of Figure 1 Clock regulates ATF4 gene expression through binding to the E-box located in the promoter region. (a) Whole-cell extracts (75 mg for Clock, and 50 mg for c-Myc and USF1) and nuclear extracts (100 mg for ATF4) were subjected to SDS-PAGE, and Western blotting analysis was performed with the indicated antibodies. Gel staining with Coomassie Brilliant Blue (CBB) is also shown. (b) Total RNA (20 mg) prepared from the indicated cells was separated on a 1% formaldehyde-agarose gel and transferred to a Hybond N þ membrane. Northern blotting analysis was performed with a Clock cDNA probe. Gel staining with ethidium bromide is also shown. (c) A ChIP assay of the PC3 cells was performed with antibodies against Clock or goat IgG. Immunoprecipitated DNAs (antigoat IgG in lanes 3 and 4, and anti-Clock IgG in lanes 5 and 6) were amplified by PCR using specific primer pairs for the ATF4 promoter region. The templates used for PCR were as follows: 1 ml (lane 2) of genomic DNA from cell lysate, and 1 ml (lanes 3 and 5) and 3 ml (lanes 4 and 6) of immunoprecipitated DNAs. Lane 1 contains a DNA size marker. The arrowhead indicates amplified partial ATF4 promoters (278 bp). The following day, they were transfected with the indicated reporter plasmids. The results were normalized to b-galactosidase activity and pGL3 promoter vector (Promega) . All values are the mean of at least three independent experiments. pGL3-PV and pGL3-BV indicate pGL3 promoter vector and pGL3 basic vector, respectively. Bars ¼ 7s.d. (f) Indicated siRNAs were transfected into PC3 cells. Whole-cell extracts (75 mg) for Clock and nuclear extracts (100 mg) for ATF4 were subjected to SDS-PAGE, and Western blotting analysis was performed.
GCLC and GSTp were upregulated in ATF4-overexpressing cells. Drug resistance is also modulated by the expression of both anti-apoptotic and apoptotic molecules. We then examined the expression of several molecules involved in apoptosis such as Bcl-2, Bcl-X L , Bax and BAK. However, we could not detect the significant alteration between drug-resistant cells and ATF4-overexpressing cells (data not shown). To explore Clock and ATF4 expression and drug resistance T Igarashi et al a potential role for glutathione, we tested BSO for its ability to reverse drug resistance in ATF4-overexpressing cells, and found that cellular sensitivity of cisplatin and etoposide was almost completely reversed by addition of BSO (Figure 5a and b). We also examined the expression of drug resistance-related genes after BSO treatment. However, no significant alteration of gene expression was observed (data not shown).
Microarray analysis of ATF4-regulated genes
Because the available information regarding the transcriptional regulation by ATF4 was limited, we used microarray technology to enable the simultaneous analysis of large numbers of genes. To confirm further transcriptional changes by the ATF4 siRNA, oligonucleotide microarray study was carried out in A549 cells treated with or without ATF4 siRNA (0.3 nM of ATF4 siRNA downregulated the cellular expression of ATF4 to 50%). Data analysis identified 121 genes, which were downregulated more than 2.5-fold and only eight genes which were upregulated (Supplementary Information). Among downregulated genes, only glutathione peroxidase 2 (GPX2) gene was identified in relation to glutathione metabolism. Then, we analysed the subset of genes for glutathione metabolism. As shown in Figure 6a , the genes for glutathione metabolism were generally downregulated by ATF4 knockdown including GCLC, glutamate-cysteine ligase modifier subunit (GCLM), g-glutamyltransferase 1 (GGT1), g-glutamyltransferase 2 (GGT2), glutamic pyruvate transaminase 2 (GPT2), GPX2, glutathione S-transferase M4 (GSTM4) and microsomal glutathione S-transferase 2 (MGST2). The ATF4-binding site was found in the proximal promoter region of these eight genes (data not shown). It was reported that GCLC was a key enzyme to determine the cellular glutathione levels and often involved in drug resistance (Tipnis et al., 1999) . To evaluate the microarray study, we carried out Western blotting analysis and revealed that the GCLC expression was downregulated by the ATF4 siRNA ( Figure 6b ). As shown in Figure 6c , the expressions of GCLC and GSTp were significantly upregulated in cisplatin-resistant cells. These data were comparable with our microarray analysis. However, the GCLC expression was not downregulated by the Clock siRNA (data not shown).
The expression of the ATP-binding cassette transporter family As shown in Table 1 , the ATF4-overexpressing cell lines showed multidrug-resistant phenotypes. It has been reported that intracellular glutathione could support the drug efflux by ATP-binding cassette (ABC) transporters (Renes et al., 2000) . Thus, we next examined the expression of major ABC transporters such as multidrug resistance protein 1 (MRP1/ ABCC1), multidrug resistance protein 2 (MRP2/ABCC2), breast cancer-resistance protein (BCRP/ABCG2) and ATF4-overexpressing cell lines A549/ATF4-5 and A549/ATF4-6. c IC50 ratio of ATF4-overexpressing cell lines to control cell lines. The cell viability after drug exposure was analysed with a WST assay. In the absence of drugs, the viability was 100%. The IC 50 of each cell line was calculated from the concentration-response curves. All values indicate the mean7standard deviation (s.d.). 5-FU, 5-fluorouracil; SN-38, 7-ethyl-10-hydroxycamptothecin. Clock and ATF4 expression and drug resistance T Igarashi et al P-glycoprotein. Interestingly, both expressions of MRP2 and BCRP were significantly upregulated in the ATF4-overexpressing cells, but MRP1 was not (Figure 7a ). We could not detect the P-glycoprotein in these cells at all. However, the ATF4-binding site was not in the promoter region of both MRP2 and BCRP genes, suggesting that both genes were not direct targets of ATF4. We confirmed the expression levels of ABC transporters were not reduced when cells were treated with BSO (Figure 7b ). We next investigated whether downregulation of BCRP or MRP2 expressions overcome etoposide or cisplatin resistance in ATF4-overexpressing cells. We prepared the specific siRNAs for both BCRP and MRP2 (Figure 7c and d) . As shown in Figure 7e , we found that downregulation of BCRP significantly decreased the IC 50 value of etoposide. On the other hand, downregulation of MRP2 significantly decreased the IC 50 value of cisplatin (Figure 7f ).
Discussion
We have previously shown that the transcription factor ATF4 can be induced by cisplatin, and that overexpression of ATF4 confers cisplatin resistance to cells (Tanabe et al., 2003) . We have also shown that ATF4 expression is a possible predictor for sensitivity to cisplatin (Tanabe et al., 2003; Kohno et al., 2005) . The current analysis explored the molecular mechanism of ATF4 expression and drug resistance.
Both expression and function of ATF4 have been reported to be regulated by the post-transcriptional pathways (Blais et al., 2004) . Phosphorylation of the a subunit of translation initiation factor (eIF2a) promotes translation of ATF4 and ATF4 phosphorylated by RSK2 increases transactivation ability (Yang et al., 2004) . We initially examined the cellular expression levels of eIF2a kinase PERK, which was activated by endoplasmic reticulum stress, in cisplatin-resistant cells. However, we could not find the significant difference of PERK expression in cisplatin-resistant cells (data not shown). Moreover, mRNA level of ATF4 was increased in cisplatin-resistant cells (Tanabe et al., 2003) then, we investigated the transcriptional regulation of ATF4. The core promoter region of ATF4 contains an E-box, so we analysed the cellular expression levels of E-box-binding proteins. Among these proteins, only Clock was overexpressed in cisplatin-resistant cell lines that were independently established (Figure 1a and b) . It has been shown that the extent of phosphorylation can determine the cellular localization and stability of Clock proteins (Lee et al., 2001) . However, Clock mRNA is also overexpressed in cisplatin-resistant cells. This indicates that cellular Clock might be involved in the transcriptional regulation in these cell lines. We confirmed the role of Clock in the regulation of ATF4 gene expression by three independent approaches: ChIP with an antiClock antibody, E-box-dependent promoter activity in reporter gene assays, and the downregulation of Clock using a siRNA strategy (Figure 1c-f) . We also demonstrated the positive correlation of Clock expression with sensitivity to cisplatin and ATF4 expression (Figure 2b and c). To investigate more clearly whether cellular expression of Clock and ATF4 contribute to chemosensitivity, siRNA oligomers were used to knockdown the expression of these transcription factors. Transfection of both Clock and ATF4 siRNAs in A549 cell led to sensitization to cisplatin and etoposide, but not to 5-FU (Figure 2d) .
It has been shown that the Per2-mutant mouse demonstrates increased sensitivity to g-radiation (Fu et al., 2002) . As the Per2 gene is regulated by Clock, it is possible that the expression of this protein might be involved in DNA damage-induced apoptosis. The analysis of the expression profile showed that several DNA damage-inducible genes such as members of the growth-arrest and DNA damage (GADD) family that block cell-cycle progression (Liebermann and Hoffman, 2002) and cyclin genes were controlled by circadian regulators (Fu et al., 2002) . Taken together, these results indicate that the cell cycle-regulating mechanism in cisplatin-resistant cells is regulated by Clock.
The second aim of our current work was to investigate the molecular mechanisms of drug resistance regulated by the Clock and ATF4 transcription system. Although Figure 4 Cellular expressions of drug resistance-related genes in ATF4-overexpressing cells (A549/ATF4-5 and A549/ATF4-6) and control cells (A549/pcDNA3-1 and A549/pcDNA3-2). Whole-cell extracts (75 mg) for GCLC, GSTp, YB-1 and nuclear extracts (100 mg) for ATF4, TopoI, TopoIIa from ATF4-overexpressing cells were subjected to SDS-PAGE, and Western blotting analysis was performed with the indicated antibodies.
Clock and ATF4 expression and drug resistance
T Igarashi et al we were unable to establish Clock-overexpressing cells, we successfully derived two ATF4-overexpressing cell lines. These cells were resistant to various anticancer agents, such as cisplatin, etoposide, doxorubicin, SN-38, and vincristine, but not to 5-FU suggesting that ATF4 contributes to the multidrug resistance of human cancer cell lines. Another important finding was the elevation of intracellular glutathione levels in these cell lines. This was consistent with the report that the ATF4 -/-cells showed impaired glutathione biosynthesis (Harding et al., 2003) . Elevated glutathione clearly contributes to drug resistance, because the depletion of glutathione by BSO was able to reverse the resistance in ATF4-overexpressing cell lines. Western blotting analysis showed that GCLC and GSTp expressions were upregulated in ATF4-overexpressing cells. Microarray data also revealed that genes for glutathione metabolism were generally downregulated in ATF4 siRNA-treated cells, suggesting that glutathione metabolism may be a key role involved in drug sensitivity. It has been reported that BSO overcomes Bcl-2-mediated drug resistance and hypothesized that BSO could possess an unique activity via mitochondria-independent pathway (Yoshida et al., 2006) . However, there are no significant changes in the expression of apoptosis-related genes (data not shown). DNA-binding activity of Clock and BMAL1 is regulated by the redox state of NAD cofactors (Rutter et al., 2001) . It would be interesting to examine the possible involvement of glutathione in regulating Clock/BMAL1 and ATF4 transcriptional activity. The oxidation-reduction status of the cell is an important regulator of various metabolic functions, and glutathione is one of the main compounds involved in reducing oxidative stresses (Dickinson and Forman, 2002) . Furthermore, glutathione S-transferases (GSTs) are ubiquitous enzymes that play an important role in drug resistance by conjugating drugs to glutathione. The genes for biosynthesis of the antioxidant glutathione were regulated by Clock and ATF4 transcription system (Figures 3b and 6b) . Thus, the cellular protection against oxidative stresses and hepatic function for drug metabolism could be regulated by the circadian rhythm, with the involvement of the transcription factor, Clock. Our findings will provide some clue that may be helpful to understand the oxidative stress-associated disorders including cancer and systemic chronotherapy.
Membrane transporters of the ABC superfamily function as a pump, and can lead to resistance against multiple anticancer agents (Gottesman et al., 2002; Clock and ATF4 expression and drug resistance T Igarashi et al Szakacs et al., 2006) . Among these transporters, P-glycoprotein and the MRP families have been extensively studied (Annereau et al., 2004) . MRP2-overexpressing cells show cross-resistance to anticancer agents such as cisplatin, doxorubicin and epirubicin (Cui et al., 1999) . BCRP can transport diverse anticancer agents, including etoposide, doxorubicin and SN-38 (Deeley et al., 2006; Krishnamurthy and Schuetz, 2006) . It has been reported that both MRP2 and GCLC are coordinately expressed in acquired drug-resistance cell lines (Ishikawa et al., 1996; Kuo et al., 1998) . Although the molecular mechanism of this is unknown, a significant correlation was found between the glutathione content and drug resistance (Fojo and Bates, 2003) . Interestingly, in our studies, both MRP2/ABCC2 and BCRP/ABCG2 were upregulated in ATF4-overexpressing cells. These two ABC transporters partially contribute to drug resistance in ATF4-overexpressing cell lines. Downregulation of BCRP partially reverse etoposide resistance but not cisplatin resistance. On the other hand, downregulation of MRP2 reverse cisplatin resistance but not etoposide resistance. These data are consistent with the previous reports that cisplatin is one of the substrates of MRP2 (Cui et al., 1999) , and etoposide is one of the substrates of BCRP (Deeley et al., 2006; Krishnamurthy and Schuetz, 2006) . Microarray analysis showed that BCRP was downregulated by the ATF4 knockdown (data not shown). High level of intracellular glutathione might be involved in the function of transcription factors, which regulate the expression of these genes. However, the regulatory mechanism of ABC transporter expression in ATF4-overexpressing cells remains unclear.
Microarray analysis is a powerful tool to identify the target genes for transcription factors. Classification according to the function suggests that ATF4 mainly mediate the cellular physiological process and metabolism (Supplementary Information). Identification of the ATF4-binding site in the 5 0 upstream from these genes and functional analysis of the promoter activity are now in progress.
In conclusion, we describe here a novel mechanism of multidrug resistance. Two transcription factors, Clock and ATF4, were unequivocally demonstrated to cause multidrug resistance in human cancer cell lines. Clock has been identified as a protein with regulating function of circadian rhythmicity, which is primary through actions at suprachiasmatic nucleus and the supraoptic nucleus (Moore, 1997) . The systemic circadian rhythm is known to be important for the clinical treatment of cancer patients (Canaple et al., 2003; Gorbacheva et al., 2005) , and our results imply that cellular rhythm can modulate cellular sensitivity to anticancer agents. Further study is required to prove the fundamental issue how cellular rhythm at a single cell level contributes to systemic chemotherapy. Regulation of Clock gene expression and Clock-targeted genes in cancer cells will be an important question to address in future work. Further, elucidation of the molecular network regulating transcription factor genes in multidrug-resistant cells should improve the understanding of genomic responses against anticancer agents and drug resistance.
Materials and methods
Cell culture
Human epidermoid cancer KB cells and human prostate cancer PC3 cells were cultured in Eagle's minimal essential medium. Human breast cancer MCF7 cells were cultured in Dulbecco's modified Eagle medium. These mediums were purchased from Nissui Seiyaku (Tokyo, Japan) and contained 10% fetal bovine serum. The cisplatin-resistant KB/CP4 and P/CDP6 cells were derived from KB and PC3 cells as described previously (Murakami et al., 2001 ) and found to be 23-63-fold more resistant to cisplatin than their parental cells (Fujii et al., 1994) . Vincristine-resistant KB/VJ300 cell derived from KB was generated as described previously (Kusaba et al., 1999) . Eleven lung cancer cell lines and newly generated Control siRNA (nM) Figure 6 The genes for glutathione metabolism are regulated by ATF4.
(a) The graph shows gene expression changes of glutathione metabolism subset mediated by ATF4 siRNA. The data were obtained from normalized and log 2-transformed microarray expression signal intensities. The samples were collected from A549 cells transfected with ATF4 siRNA (50 or 0.3 nM) and control siRNA (50 or 0.3 nM) in duplicate. Eight GeneChips were used for analysis and duplicated GeneChip data was averaged for each of the four conditions. The subset of genes was further selected if fold change marked >1.5 between averaged ATF4 siRNA and control siRNA samples. (b) Whole-cell lysates (50 mg) from A549 cells transfected with indicated siRNAs were subjected to SDS-PAGE, and Western blotting analysis was performed with anti-GCLC antibody. Gel staining with CBB is also shown. (c) Western blotting analysis with whole-cell lysates (50 mg) from cisplatin sensitive/resistant cells was performed with anti-GCLC and anti-GSTp antibodies.
Clock and ATF4 expression and drug resistance T Igarashi et al ATF4-overexpressing cell lines were described previously (Tanabe et al., 2003) . Cell lines were maintained in a 5% CO 2 atmosphere at 371C.
Antibodies and drugs
Antibodies against c-Myc (sc-764), Clock (sc-6927), USF1 (sc-8983), ATF4 (sc-200), TopoI (sc-5342), TopoIIa (sc-5346), GCLC (gGCSc, sc-22755), Stat3 (sc-482) and donkey anti-goat IgG (sc-2020) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-BCRP (MAB4146) and MRP2 (MAB4150) antibodies were purchased from Chemicon (Temecula, CA, USA). Anti-MRP1 and anti-P-glycoprotein antibodies were purchased from MONOSAN (Netherlands) and Fujirebio Diagnostic (Malvern, PA, USA), respectively. Anti-YB-1 (Ohga et al., 1996) and anti-GSTp (Saburi et al., 1989) antibodies were prepared as described previously. Cisplatin, vincristine, 5-FU), etoposide, BSO) were purchased from Sigma (St Louis, MO, USA). Doxorubicin was purchased from Kyowa Hakko Kogyo Co. Ltd, (Tokyo, Japan). 7-Ethyl-10-hydroxycamptothecin (SN-38) was kindly gifted by Yakult Co. Ltd. (Tokyo, Japan). Clock and ATF4 expression and drug resistance T Igarashi et al
Plasmid construction
To obtain the full-length complementary DNA (cDNAs) of Clock and BMAL1, polymerase chain reaction (PCR) was carried out on a SuperScript cDNA library (Invitrogen Life Technologies, CA, USA) using the following primer pairs (single underlining indicates the start codons): ATGTTGTT TACCGTAAGCTGTAG and CTACTGTGGTTGAACCT TGGAAG for Clock; and ATGGCAGACCAGAGAATG GAC and TTACAGCGGCCATGGCAAGTC for BMAL1. These PCR products were cloned into the pGEM-T easy vector (Promega, Madison, WI, USA). To construct mammalian expression plasmids, the NotI Clock cDNA fragment and the EcoRI BMAL1 cDNA fragment were ligated into the pcDNA3 vector (Invitrogen). The core promoter and the partial first exon (-94 to þ 81) of ATF4 were amplified by PCR using the placenta DNA and the following primer pairs: AGATCTGAGACGGTCACGTGGTCGCGGC and AAG CTTGGCCGTGGACCCTGAGGGC. PCR was also performed to obtain the E-box-mutant promoter of the ATF4 using the following primer pairs: AGATCTGAGACGGTC CTTGGGTCGCGGC and AAGCTTGGCCGTGGACCCT GAGGGC. Single and double underlining indicate the wildtype and mutated E-box, respectively. These PCR products were cloned and ligated into the BglII-HindIII site of the pGL3-basic vector (Promega). ATF4-WT-Luc and ATF4-MT-Luc plasmids contain a wild-type and mutated E-box, respectively.
Northern blotting analysis
Northern blotting analysis was performed as described previously (Uramoto et al., 2002) . RNA samples (20 mg/lane) were separated on a 1% formaldehyde-agarose gel and transferred to a Hybond N þ membrane (Amersham Biosciences, Piscataway, NJ, USA) with 10 Â SSC. After prehybridization and hybridization with radiolabeled cDNA fragment of Clock, signal intensities were quantified using a bio-imaging analyzer (BAS2000, Fuji Film, Co. Ltd, Tokyo, Japan).
Western blotting analysis
Whole-cell lysates and nuclear extract were prepared as described previously (Uramoto et al., 2002) . The indicated amounts of whole-cell lysate or nuclear extract were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Immunoblotting analysis was performed with an appropriate dilution of the antibodies, and the membrane was developed using a chemiluminescence protocol (Amersham Biosciences).
Chromatin immunoprecipitation assay
The ChIP assay was performed as described previously (Uramoto et al., 2002) . Soluble chromatin from 1 Â 10 6 cells was incubated with 2 mg anti-Clock antibody or anti-goat immunoglobulin G (IgG). The purified DNA was dissolved with 20 ml dH 2 O. The DNA (1 or 3 ml) was then used for PCR analysis with the following primer pairs for the ATF4 promoter region (-241-þ 38): GACTCTGATCATAGAAGC CTAG forward primer and GCAGAGAAAACTACAT CTGTGG reverse primer. The PCR products were separated by electrophoresis on a 2% agarose gel and stained with ethidium bromide.
Transient transfection and luciferase assay Transient transfection and a luciferase assay were performed as described previously (Uramoto et al., 2002) . The indicated amounts of the ATF4 reporter plasmid and the expression plasmid were co-transfected using Superfect reagent (Qiagen, Hilden, Germany). After transfection, the cells were cultured for 48 h. Luciferase activity was detected by a Picagene kit (Toyoinki, Tokyo, Japan), and the light intensity was measured with a luminometer (Luminescencer JNII RAB-2300; ATTO, Japan). All of the cells were co-transfected with pCH110 as a control for transfection efficiency. The results shown are normalized to b-galactosidase activity and are representative of at least three independent experiments.
Knockdown analysis using siRNAs
The following double-stranded RNA 25 base pair oligonucleotides were generated from Stealth Select RNAi ( for MRP2/AB CC2. siRNA transfections were performed according to the manufacturer's instructions (Invitrogen) with modification. Ten microliters of Lipofectamine 2000 (Invitrogen) was diluted in 250 ml Opti-MEM I medium (Invitrogen) and incubated for 5 min at room temperature. Next, 250 pmol of Clock, ATF4, and inverted control duplex Stealth RNA (Invitrogen) diluted in 250 ml Opti-MEM I were added gently and incubated for 20 min at room temperature. Oligomer-lipofectamine complexes and aliquots of 1 Â 10 6 A549 cells in 500 ml culture medium were combined and incubated for 10 min at room temperature. Aliquots of 300 cells were used for a colonyformation assay as described below. The remaining cells were seeded in 100 mm dishes with 10 ml culture medium and harvested after 96 h culture for Western blotting analysis as described above.
Cytotoxicity analysis by colony formation and WST-8 assays For the colony-formation assay, 300 cells transfected with siRNAs were seeded in 35 mm dishes with 2 ml culture medium. The following day, the cells were treated with the indicated concentrations of cisplatin, etoposide and 5-FU. Seven days post-transfection, the numbers of colonies were counted. For the water-soluble tetrazolium salt (WST)-8 assay, 1.5 Â 10 3 ATF4-overexpressing cells or 4 Â 10 3 P/CDP6 cells transfected with indicated amounts of siRNAs were seeded in 96-well plates. The following day, the indicated concentrations of the drugs were applied. After 72 h, the surviving cells were stained with TetraColor ONE (Seikagaku Corporation, Tokyo, Japan) for 90 min at 371C according to the manufacturer's instructions. The absorbance was then measured at 450 nm. For the WST-8 assay with BSO, 10 mM BSO were treated when ATF4-overexpressing cells were seeded, and the following day the indicated concentrations of the drugs were applied.
Quantitative analysis of intracellular glutathione Aliquots of 5 Â 10 5 ATF4-transfected cells treated with or without 10 mM BSO for 72 h, and siRNA-transfected A549 cells were washed twice with phosphate-buffered saline. Then, 10 nmol/l HCl was added to the cells and they were rapidly freeze-thawed twice. Next, 5% sulfosalicylic acid was added and the cell lysates were centrifuged at 8000 g for 10 min at room temperature. The intracellular glutathione concentration of the supernatants was measured using the Total Glutathione Quantification Kit (Dojindo Molecular Technologies, Kumamoto, Japan) according to the manufacturer's instructions.
Oligonucleotide microarray study and microarray analysis A microarray procedure was performed as described previously (Arao et al., 2006) . In brief, total RNA extracts were collected from A549 cells transfected with ATF4 siRNA (50 or 0.3 nM) or control siRNA (50 or 0.3 nM) in duplicate. Eight GeneChips (Affymetrix, Santa Clara, CA, USA) were used for analysis. The microarray analysis were performed using the BRB Array Tools software ver. 3.3.0 (http://linus.nci.nih.gov/ BRB-ArrayTools.html) developed by Dr Richard Simon and Amy Peng. In brief, a log base 2 transformation was applied to the microarray raw data, and global normalization was used to median over entire array. Genes were excluded if percent of data missing or filtered out exceeds 20%. We analysed subset of genes including glutathione metabolism subset (based on KEGG PATHWAY Database, http://www.genome.jp/kegg/ pathway.html). The selected genes were further selected if fold change marked >1.5 between averaged ATF4 siRNA sample and control siRNA samples. Next, the 129 genes that fold change marked >2.5 between averaged ATF4 siRNA sample and control siRNA samples from all normalized and filtered genes were listed and clustered in Supplementary Information.
Statistical analysis
Expression levels of Clock, ATF4, and c-Myc were assessed numerically with the NIH image program (NIH, Bethesda, MD, USA). The Pearson correlation was used for statistical analysis, and significance was set at the 5% level.
